Drug Trial Radar · NCT00433732
To Evaluate the Safety and Efficacy of Trexima in the Acute Treatment of Migraine Headaches
Last checked: Nov 19, 2026Latest source record: Feb 12, 2007 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,400
Actual
Start
Aug 2004
Primary completion
Not stated
Study completion Apr 2005
Sponsor
- Lead sponsor
- POZENIndustry
- Sponsor type
- Industry
- First posted
- Feb 12, 2007
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To determine the efficacy of the Trexima versus placebo as assessed by pain relief and the incidences of photophobia, phonophobia and nausea at 2 hours after treatment as the primary endpoints.
Conditions
- Migraine Headaches
Interventions
sumatriptanDrug
naproxen sodiumDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Trexima will be evaluated for efficacy as an acute treatment for migraine based on its superiority over placebo at 2 hours for: a) pain relief (no or mild pain), b) incidence of photophobia, c) incidence of phonophobia and d) incidence of nausea.
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Little Rock Family Practice Clinic
Little Rock, Arkansas
Pozen, Inc.
Chapel Hill, North Carolina
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.